SOURCE: TriMarkPublications.com

TriMarkPublications.com

July 21, 2011 14:34 ET

Drugs of Abuse Testing Revenue Forecasted to Jump to $2.7 Billion by 2015

NEW YORK, NY--(Marketwire - Jul 21, 2011) - TriMarkPublications.com cites in its newly published "Drugs of Abuse Testing Markets" report that drugs of abuse testing revenue is forecasted to jump to $2.7 billion by 2015. For more information, visit: http://www.trimarkpublications.com/products/Drugs-of-Abuse-Testing-Markets.html.

Drugs of abuse usage is tested for using five main human samples: urine, hair follicles, oral fluid, sweat and blood. Urine testing is currently the gold standard due to its accuracy and reliability. Substance abuse in the U.S. costs society over $510 billion annually; over 60% of U.S. employers have a drug testing policy in place.

The "Drugs of Abuse Testing Markets" report covers:

  • Amphetamines
  • Tricyclic Antidepressants (TCAs)
  • Barbiturates
  • Benzodiazepines
  • Cannabinoids/Marijuana
  • Cocaine
  • Lysergic Acid Diethylamide (LSD)
  • Methadone
  • Methaqualone and Phencyclidine (PCP)
  • Opiates - Heroin and OxyContin
  • Alcohol Testing

The "Drugs of Abuse Testing Markets" report examines companies manufacturing drugs of abuse testing equipment and supplies in the world. Companies covered include: Abbott, Agilent Technologies, Alere, Alfa Scientific Designs, Alpha Scientific Designs, American Bio Medica, American Biomedica, Avitar, APP, Beckman Coulter, Bio-Rad, Biophor, Bioscan Screening Systems, Carolina Chemistries, Concateno, First Check Medical, CEL-SCI, Medica, Orasure, Ortho Clinical, Pathtech, Phamatech, Princeton Biomeditech, Randox, Roche, MerLion, Tcpi, Tecan and Thermo Fisher Scientific.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/products/Drugs-of-Abuse-Testing-Markets.html.

About TriMarkPublications.com

TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information